论文部分内容阅读
目的:观察丹叶胶囊治疗慢性乙型肝炎肝纤维化的临床疗效及对外周血T淋巴细胞亚群的影响。方法:80例慢性乙型肝炎肝纤维化患者被随机分为2组,对照组给予基础的西药护肝治疗,治疗组在此基础上加用丹叶胶囊治疗,疗程为24周,治疗1个疗程判定疗效。结果:治疗结束后,两组肝功能ALT、AST、TB均较前明显下降(P<0.01),二者比较无显著性差异(P>0.05)。治疗组肝纤维化血清标志物HA、LN、P-Ⅲ-P、Ⅳ-C较前明显下降,优于对照组(P<0.01)。治疗后治疗组T淋巴细胞亚群各指标CD3+、CD4+、CD4+/CD8+均较前明显上升,具有显著性差异(其中CD3+、CD4+/CD8+的P<0.01,CD4+的P值<0.05),CD8+较前下降,具有显著性差异(P<0.01),治疗后CD3+、CD4+、CD4+/CD8+均比对照组高,具有显著性差异(其中CD4+、CD4+/CD8+的P<0.01,CD3+的P值<0.05),而CD8+则比对照组低(P<0.01)。结论丹叶胶囊能有效改善慢性乙型肝炎肝纤维化患者的血清纤维化指标及提高机体免疫功能。
Objective: To observe the clinical efficacy of Danye Capsule in treating chronic hepatitis B liver fibrosis and its effect on peripheral blood T lymphocyte subsets. Methods: Eighty patients with chronic hepatitis B liver fibrosis were randomly divided into two groups. The control group was given basic western medicine liver protection treatment. On the basis of this, the treatment group was treated with Danye capsule for 24 weeks. One treatment group Treatment to determine the efficacy. Results: At the end of treatment, ALT, AST and TB of liver function in both groups were significantly lower than those before (P <0.01). There was no significant difference between the two groups (P> 0.05). The serum levels of HA, LN, P-Ⅲ-P and Ⅳ-C in the treatment group were significantly lower than those in the control group (P <0.01). After treatment, the levels of CD3 +, CD4 +, CD4 + / CD8 + of T lymphocyte subsets in the treatment group were significantly increased compared with those before treatment (P <0.01 for CD4 + / CD8 + and P <0.05 for CD4 + / CD8 + (P <0.01). The CD3 +, CD4 +, CD4 + / CD8 + were significantly higher than those in the control group after treatment (P <0.01 for CD4 +, CD4 + / CD8 + and P <0.05 for CD3 + ), While CD8 + was lower than the control group (P <0.01). Conclusion Danye Capsule can effectively improve serum fibrosis indexes and improve immune function in patients with chronic hepatitis B liver fibrosis.